Document:

Exhibit 10.1

 

Subscription
Agreement

 

THE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION.
THERE ARE FURTHER RESTRICTIONS ON THE TRANSFERABILITY OF THE SECURITIES DESCRIBED HEREIN.

 

THE
PURCHASE OF THE SECURITIES INVOLVES A HIGH DEGREE OF RISK AND SHOULD BE CONSIDERED ONLY BY PERSONS WHO CAN BEAR THE RISK OF THE
LOSS OF THEIR ENTIRE INVESTMENT.

 

HEALTHLYNKED
CORP.

1726
Medical Blvd., Suite 101, 

Naples,
Florida 34110

 

Article
I 

 

Ladies
and Gentlemen:

 

The
undersigned understands that HEALTHLYNKED CORP., a corporation organized under the laws of Nevada (the “Company”),
is offering an aggregate of _________ shares of its common stock, par value $0.0001 per share (the “Securities”)
in a private placement. The undersigned further understands that the offering is being made without registration of the Securities
under the Securities Act of 1933, as amended (the “Securities Act”), or any securities law of any state of the
United States or of any other jurisdiction, and is being made only to “accredited investors” (as defined in Rule 501
of Regulation D under the Securities Act).

 

1.            Subscription. Subject to the terms and conditions hereof, the undersigned hereby irrevocably subscribes for the Securities
set forth in Appendix A hereto for the aggregate purchase price set forth in Appendix A, which is payable as described in Section
4 hereof. The undersigned acknowledges that the Securities will be subject to restrictions on transfer as set forth in this
subscription agreement (the “Subscription Agreement”).

 

2.            Acceptance of Subscription and Issuance of Securities. It is understood and agreed that the Company shall have the sole
right, at its complete discretion, to accept or reject this subscription, in whole or in part, for any reason and that the same
shall be deemed to be accepted by the Company only when it is signed by a duly authorized officer of the Company and delivered
to the undersigned at the Closing referred to in Section 3 hereof. Subscriptions need not be accepted in the order received,
and the Securities may be allocated among subscribers. Notwithstanding anything in this Subscription Agreement to the contrary,
the Company shall have no obligation to issue any of the Securities to any person who is a resident of a jurisdiction in which
the issuance of Securities to such person would constitute a violation of the securities, “blue sky” or other similar
laws of such jurisdiction (collectively referred to as the “State Securities Laws”).

 

     

     

    

 

3.            The Closing. The closing of the purchase and sale of the Securities (the “Closing”) shall take place at
the offices of the Company, at 10:00 a.m. on ___________, or at such other time and place as the Company may designate by notice
to the undersigned.

 

4.            Payment for Securities. Payment for the Securities shall be received by the Company from the undersigned by wire transfer
of immediately available funds or other means approved by the Company at or prior to the Closing, in the amount as set forth in
Appendix A hereto. The Company shall deliver certificates representing the Securities to the undersigned at the Closing bearing
an appropriate legend referring to the fact that the Securities were sold in reliance upon an exemption from registration under
the Securities Act.

 

5.            Representations and Warranties of the Company. As of the Closing, the Company represents and warrants that:

 

(a)          The Company is duly formed and validly existing under the laws of Nevada, with full power and authority to conduct its business
as it is currently being conducted and to own its assets; and has secured any other authorizations, approvals, permits and orders
required by law for the conduct by the Company of its business as it is currently being conducted.

 

(b)          The Company has all requisite to issue and sell the Securities, enter into this Subscription Agreement and to perform all the
obligations required to be performed by it hereunder, and such purchase will not contravene any law, rule or regulation binding
on the Company.

 

(c)          The Securities have been duly authorized and, when issued, delivered and paid for in the manner set forth in this Subscription
Agreement, will be validly issued, fully paid and nonassessable.

 

(d)          Except as a result of the purchase and sale of the Securities and as disclosed in the SEC Reports, there are no outstanding options,
warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or
obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any
shares of common stock, or contracts, commitments, understandings or arrangements by which the Company is or may become bound
to issue additional shares of common stock or securities convertible or exercisable into common stock (the “Common Stock
Equivalents”). 

 

    	 	2	 

     

    

 

(e)          The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under
the Securities Act and the Exchange Act of 1934, as amended (the “Exchange Act”), including pursuant to Section 13(a) or
15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or
regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference
therein, and the Company’s registration statements on Form S-1 and Form S-8, being collectively referred to herein as the
“SEC Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any
such SEC Reports prior to the expiration of any such extension.  As of their respective dates, the SEC Reports complied in
all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports,
when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting
requirements and the rules and regulations of the Securities and Exchange Commission (the “Commission”)
with respect thereto as in effect at the time of filing.  Such financial statements have been prepared in accordance with
United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company
as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case
of unaudited statements, to normal, immaterial, year-end audit adjustments.

 

(f)           Since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in
a subsequent SEC Report filed prior to the date hereof, (i) there has been no event, occurrence or development that has had
or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities
(contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business
consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements
pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting,
(iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased,
redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued
any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans.  The
Company does not have pending before the Commission any request for confidential treatment of information.  “Material
Adverse Effect” means (i) a material adverse effect on the legality, validity or enforceability of this Subscription
Agreement, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial
or otherwise) of the Company and its subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s
ability to perform in any material respect on a timely basis its obligations under this Subscription Agreement.

 

    	 	3	 

     

    

 

(g)          There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company, any subsidiary or any of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”)
which adversely affects or challenges the legality, validity or enforceability of any of this Subscription Agreement or the Securities. 
Neither the Company nor any subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving
a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.  There
has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving
the Company or any current or former director or officer of the Company.  The Commission has not issued any stop order or
other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange
Act or the Securities Act.

 

6.            Representations and Warranties of the Undersigned. The undersigned hereby represents and warrants to and covenants with
the Company that:

 

(a)          General.

 

(i)          The undersigned has all requisite authority (and in the case of an individual, the capacity) to purchase the Securities, enter
into this Subscription Agreement and to perform all the obligations required to be performed by the undersigned hereunder, and
such purchase will not contravene any law, rule or regulation binding on the undersigned or any investment guideline or restriction
applicable to the undersigned.

 

(ii)         The undersigned is a resident of the state set forth on the signature page hereto and is not acquiring the Securities as a nominee
or agent or otherwise for any other person.

 

(iii)        The undersigned will comply with all applicable laws and regulations in effect in any jurisdiction in which the undersigned purchases
or sells Securities and obtain any consent, approval or permission required for such purchases or sales under the laws and regulations
of any jurisdiction to which the undersigned is subject or in which the undersigned makes such purchases or sales, and the Company
shall have no responsibility therefor.

 

(b)          Information Concerning the Company.

 

(i)          The undersigned has access to and carefully reviewed the Company’s SEC Reports and has had on opportunity for a reasonable
period of time prior to the date hereof to obtain additional information concerning the offering of the Securities, the Company,
and all other information to the extent the Company possesses such information or can acquire it without unreasonable effort or
expense.

 

    	 	4	 

     

    

 

(ii)         The undersigned understands and accepts that the purchase of the Securities involves various risks, including the risks outlined
in the SEC Reports and this Subscription Agreement. The undersigned represents that it is able to bear any loss associated with
an investment in the Securities.

 

(iii)        The undersigned confirms that it is not relying on any communication (written or oral) of the Company or any of its affiliates,
as investment advice or as a recommendation to purchase the Securities. It is understood that information and explanations related
to the terms and conditions of the Securities provided by the Company or any of its affiliates shall not be considered investment
advice or a recommendation to purchase the Securities, and that neither the Company nor any of its affiliates is acting or has
acted as an advisor to the undersigned in deciding to invest in the Securities. The undersigned acknowledges that neither the
Company nor any of its affiliates has made any representation regarding the proper characterization of the Securities for purposes
of determining the undersigned’s authority to invest in the Securities.

 

(iv)        The undersigned is familiar with the business and financial condition and operations of the Company, all as generally described
in the SEC Reports. The undersigned has had access to such information concerning the Company and the Securities as it deems necessary
to enable it to make an informed investment decision concerning the purchase of the Securities.

 

(v)         The undersigned understands that, unless the undersigned notifies the Company in writing to the contrary at or before the Closing,
each of the undersigned’s representations and warranties contained in this Subscription Agreement will be deemed to have been
reaffirmed and confirmed as of the Closing, taking into account all information received by the undersigned.

 

(vi)        The undersigned acknowledges that the Company has the right in its sole and absolute discretion to abandon this private placement
at any time prior to the completion of the offering. This Subscription Agreement shall thereafter have no force or effect and
the Company shall return the previously paid subscription price of the Securities, without interest thereon, to the undersigned.

 

(vii)       The undersigned understands that no federal or state agency has passed upon the merits or risks of an investment in the Securities
or made any finding or determination concerning the fairness or advisability of this investment.

 

(c)          Non-reliance.

 

(i)          The undersigned represents that it is not relying on (and will not at any time rely on) any communication (written or oral) of
the Company, as investment advice or as a recommendation to purchase the Securities.

 

    	 	5	 

     

    

 

(ii)         The undersigned confirms that the Company has not (A) given any guarantee or representation as to the potential success, return,
effect or benefit (either legal, regulatory, tax, financial, accounting or otherwise) of an investment in the Securities or (B)
made any representation to the undersigned regarding the legality of an investment in the Securities under applicable legal investment
or similar laws or regulations. In deciding to purchase the Securities, the undersigned is not relying on the advice or recommendations
of the Company and the undersigned has made its own independent decision that the investment in the Securities is suitable and
appropriate for the undersigned.

 

(d)          Status of Undersigned.

 

(i)          The undersigned has such knowledge, skill and experience in business, financial and investment matters that the undersigned is
capable of evaluating the merits and risks of an investment in the Securities. With the assistance of the undersigned’s own professional
advisors, to the extent that the undersigned has deemed appropriate, the undersigned has made its own legal, tax, accounting and
financial evaluation of the merits and risks of an investment in the Securities and the consequences of this Subscription Agreement.
The undersigned has considered the suitability of the Securities as an investment in light of its own circumstances and financial
condition and the undersigned is able to bear the risks associated with an investment in the Securities and its authority to invest
in the Securities.

 

(ii)         The undersigned is an “accredited investor” as defined in Rule 501(a) under the Securities Act. The undersigned agrees
to furnish any additional information requested by the Company or any of its affiliates to assure compliance with applicable U.S.
federal and state securities laws in connection with the purchase and sale of the Securities. The undersigned acknowledges that
the undersigned has completed the Investor Questionnaire contained in Appendix B and that the information contained therein is
complete and accurate as of the date thereof and is hereby affirmed as of the date hereof. Any information that has been furnished
or that will be furnished by the undersigned to evidence its status as an accredited investor is accurate and complete, and does
not contain any misrepresentation or material omission.

 

(e)          Restrictions on Transfer or Sale of Securities. As applies to the Purchaser:

 

(i)          The undersigned is acquiring the Securities solely for the undersigned’s own beneficial account, for investment purposes,
and not with a view to, or for resale in connection with, any distribution of the Securities. The undersigned understands that
the Securities have not been registered under the Securities Act or any State Securities Laws by reason of specific exemptions
under the provisions thereof which depend in part upon the investment intent of the undersigned and of the other representations
made by the undersigned in this Subscription Agreement. The undersigned understands that the Company is relying upon the representations
and agreements contained in this Subscription Agreement (and any supplemental information) for the purpose of determining whether
this transaction meets the requirements for such exemptions.

 

    	 	6	 

     

    

 

(ii)         The undersigned understands that the Securities are “restricted securities” under applicable federal securities laws
and that the Securities Act and the rules of the Commission provide in substance that the undersigned may dispose of the Securities
only pursuant to an effective registration statement under the Securities Act or an exemption therefrom, and the undersigned understands
that the Company has no obligation or intention to register any of the Securities, or to take action so as to permit sales pursuant
to the Securities Act (including Rule 144 thereunder). Accordingly, the undersigned understands that under the Commission’s rules,
the undersigned may dispose of the Securities principally only in “private placements” which are exempt from registration
under the Securities Act, in which event the transferee will acquire “restricted securities” subject to the same limitations
as in the hands of the undersigned. Consequently, the undersigned understands that the undersigned must bear the economic risks
of the investment in the Securities for an indefinite period of time.

 

(iii)        The undersigned agrees: (A) that the undersigned will not sell, assign, pledge, give, transfer or otherwise dispose of the Securities
or any interest therein, or make any offer or attempt to do any of the foregoing, except pursuant to a registration of the Securities
under the Securities Act and all applicable State Securities Laws, or in a transaction which is exempt from the registration provisions
of the Securities Act and all applicable State Securities Laws; (B) that the certificates representing the Securities will bear
a legend making reference to the foregoing restrictions; and (C) that the Company and it affiliates shall not be required to give
effect to any purported transfer of such Securities except upon compliance with the foregoing restrictions.

 

(iv)        The undersigned acknowledges that neither the Company nor any other person offered to sell the Securities to it by means of any
form of general solicitation or advertising, including but not limited to: (A) any advertisement, article, notice or other communication
published in any newspaper, magazine or similar media or broadcast over television or radio or (B) any seminar or meeting whose
attendees were invited by any general solicitation or general advertising.

 

7.            Conditions to Obligations of the Undersigned and the Company. The obligations of the undersigned to purchase and pay for
the Securities specified in Appendix A and of the Company to sell the Securities are subject to the satisfaction at or prior to
the Closing of the following conditions precedent: the representations and warranties of the Company contained in Section 5
hereof and of the undersigned contained in Section 6 hereof shall be true and correct as of the Closing in all respects
with the same effect as though such representations and warranties had been made as of the Closing.

 

    	 	7	 

     

    

 

8.            Obligations Irrevocable. The obligations of the undersigned shall be irrevocable.

 

9.            Legend. The certificates representing the Securities sold pursuant to this Subscription Agreement will be imprinted with
a legend in substantially the following form:

 

“THE
SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED EXCEPT (1) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OR (2) PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE STATE SECURITIES LAWS AND THE SECURITIES LAWS
OF OTHER JURISDICTIONS, AND IN THE CASE OF A TRANSACTION EXEMPT FROM REGISTRATION, UNLESS THE COMPANY HAS RECEIVED AN OPINION
OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT AND SUCH
OTHER APPLICABLE LAWS.”

 

10.          Lock-Up of Securities. The undersigned will not, for a period commencing on the date hereof and ending six months thereafter,
(1) offer, pledge, sell, contract to sell, grant any option or contract to purchase, purchase any option or contract to sell,
or otherwise dispose of, directly or indirectly, any Securities of the Company purchased under this Subscription Agreement, (2)
enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of such Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of such Securities,
in cash or otherwise.

 

11.          Waiver, Amendment. Neither this Subscription Agreement nor any provisions hereof shall be modified, changed, discharged
or terminated except by an instrument in writing, signed by the party against whom any waiver, change, discharge or termination
is sought.

 

12.          Assignability. Neither this Subscription Agreement nor any right, remedy, obligation or liability arising hereunder or
by reason hereof shall be assignable by either the Company or the undersigned without the prior written consent of the other party.

 

13.          Waiver of Jury Trial. THE UNDERSIGNED IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY WITH RESPECT TO ANY LEGAL PROCEEDING
ARISING OUT OF THE TRANSACTIONS CONTEMPLATED BY THIS SUBSCRIPTION AGREEMENT.

 

    	 	8	 

     

    

 

14.          Submission to Jurisdiction. With respect to any suit, action or proceeding relating to any offers, purchases or sales of
the Securities by the undersigned (“Proceedings”), the undersigned irrevocably submits to the jurisdiction of
the federal or state courts located in the Borough of Manhattan in New York City, which submission shall be exclusive unless none
of such courts has lawful jurisdiction over such Proceedings.

 

15.          Governing Law. This Subscription Agreement shall be governed by and construed in accordance with the laws of the State
of New York.

 

16.          Section and Other Headings. The section and other headings contained in this Subscription Agreement are for reference purposes
only and shall not affect the meaning or interpretation of this Subscription Agreement.

 

17.          Counterparts. This Subscription Agreement may be executed in any number of counterparts, each of which when so executed
and delivered shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.

 

18.          Notices. All notices and other communications provided for herein shall be in writing and shall be deemed to have been
duly given if delivered personally or sent by registered or certified mail, return receipt requested, postage prepaid to the following
addresses (or such other address as either party shall have specified by notice in writing to the other):

 

	If
    to the Company:	HealthLynked
        Corp.

        1726
Medical Blvd Suite 101, Naples,

        Florida 34110

        

        Facsimile:

        

        E-mail:

        

        Attention:Chief
        Financial Officer

	 	 
	with
    a copy to:	Sichenzia
        Ross Ference Kesner LLP

        

        Facsimile:212
        930 9725

        

        E-mail:
        gsichenzia@srfkllp.com

        

        Attention:Gregory
        Sichenzia

	 	 
	If
    to the Purchaser:	Facsimile:

        

        E-mail:

        

        Attention:

	 	 
	with
    a copy to:	Facsimile:

        E-mail:

        

        Attention:

 

    	 	9	 

     

    

 

19.          Binding Effect. The provisions of this Subscription Agreement shall be binding upon and accrue to the benefit of the parties
hereto and their respective heirs, legal representatives, successors and assigns.

 

20.          Entire Agreement. This Subscription Agreement constitutes the entire agreement and supersedes all prior and contemporaneous
agreements and understandings among the parties with respect to the subject matter hereof and thereof.

 

21.          Survival. All representations, warranties and covenants contained in this Subscription Agreement shall survive (i) the
acceptance of the subscription by the Company and the Closing, (ii) changes in the transactions, documents and instruments described
herein which are not material or which are to the benefit of the undersigned and (iii) the death or disability of the undersigned.

 

22.          Notification of Changes. The undersigned hereby covenants and agrees to notify the Company upon the occurrence of any event
prior to the closing of the purchase of the Securities pursuant to this Subscription Agreement which would cause any representation,
warranty, or covenant of the undersigned contained in this Subscription Agreement to be false or incorrect.

 

23.          Severability. If any term or provision of this Subscription Agreement is invalid, illegal or unenforceable in any jurisdiction,
such invalidity, illegality or unenforceability shall not affect any other term or provision of this Subscription Agreement or
invalidate or render unenforceable such term or provision in any other jurisdiction.

 

 

 

[SIGNATURE
PAGE FOLLOWS]

 

    	 	10	 

     

    

 

IN
WITNESS WHEREOF, the undersigned has executed this Subscription Agreement this ____ OF ___________, _________.

 

	PURCHASER
    (if an individual):	 	PURCHASER
    (if an entity):
	 	 	 	 	 
	By	                 	 	                    
		 	 	Legal
                                         Name of Entity 

	Name:	 	 	 
		 	 	By	            
	 	 	 	Name:

        
	 
	 	 	 	Title:	 

 

State/Country
of Domicile or Formation: ______________________________________

 

Aggregate
Subscription Amount:

US$_________________________________________

 

The
offer to purchase Securities as set forth above is confirmed and accepted by the Company as to __________ shares of common stock.

 

	 	HEALTHLYNKED CORP.
	 	 	 
	 	By:	                   
	 	Name:	 
	 	Title:	 

 

    	 	11	 

     

    

 

APPENDIX
A

 

Consideration
To Be Delivered

 

	Securities
    to Be Acquired	Aggregate
    Purchase Price to be Paid
	 	 
	_________
    shares of common stock	US$
    ___________   

 

 

12Exhibit 4.1

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

FORM
OF CLASS A COMMON STOCK PURCHASE WARRANT 

 

ORIGINCLEAR,
inc. 

 

Warrant
No.                                                                                                                                                                        Issue Date:       , 2017

 

THIS
CLASS A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received,           (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after the the date hereof (the “Initial Exercise Date”) and on or prior to the close of business
on June 1, 2018 (the “Termination Date”) but not thereafter, to subscribe for and purchase from OriginClear,
Inc., a Nevada corporation (the “Company”), up to           shares (the “Warrant Shares”)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b).

 

Section
1.             Definitions. For the purposes hereof, in addition to the terms defined elsewhere in this Warrant, (a) capitalized
terms not otherwise defined herein shall have the meanings set forth in the Subscription Agreement and (b) the following terms
shall have the following meanings:

 

“Business
Day” means any day except any Saturday, any Sunday, any day which shall be a federal legal holiday in the United
States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental
action to close.

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof
to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other
instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to
receive Common Stock.

 

“Fair
Market Value” of one share of Common Stock as of a particular date shall mean: (i) if traded on a National Securities
Exchange, the VWAP (as defined below) of the Common Stock of the Company on such exchange over the five (5) Trading Days ending
immediately prior to the applicable date of valuation; (ii) if quoted on the OTCQB or the OTCPink or its successor, the average
VWAP over the thirty (30) Trading Days ending immediately prior to the applicable date of valuation; and (iii) if neither (i)
nor (ii) applies, the Fair Market Value shall be the value thereof, as agreed upon by the Company and the Holder; provided, however,
that if the Company and the Holder cannot agree on such value, such value shall be determined by an independent valuation firm
experienced in valuing businesses such as the Company and jointly selected in good faith by the Company and the Holder. Fees and
expenses of the valuation firm shall be paid for by the Company.

 

    	 	 	1

     

    

 

“National
Securities Exchange” means the following markets or exchanges on which the Common Stock may be listed or quoted
for trading on the date in question: the NYSE MKT, LLC, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global
Select Market, the New York Stock Exchange.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Subscription
Agreement” means, collectively, the Subscription Agreement, dated as of ___, 2017, between the Company and the original
Holder, as amended, modified or supplemented from time to time in accordance with its terms.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Trading
Day” means a day on which the New York Stock Exchange is open for business.

 

“Trading
Market” means the following markets or exchanges on which the Common Stock is listed or quoted for trading on the
date in question: the NYSE AMEX LLC, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the
New York Stock Exchange, the OTCQB or the OTCPink.

 

“Transaction
Documents” shall have the meaning set forth in the Subscription Agreement.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a National Securities Exchange, the daily volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on the trading market on which the Common Stock is then listed or quoted as reported by Bloomberg
L.P. (based on a Trading Day from 9:30 a.m. New York City time to 4:02 p.m. New York City time); (b) if the Common Stock is quoted
on any one or more of the OTC Bulletin Board, or the other OTC markets, including the OTCQX, OTCQB and OTCPink, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTC Markets, including the OTCQX, OTCQB and
the OTCPink; or (cd) in all other cases, the Fair Market Value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Subscribers of a majority in interest of the Securities then outstanding and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company; provided that in each case where Bloomberg L.P. data
is being relied upon, Holder shall provide to the Company a copy of such information for the Company's records.

 

    	 	 	2

     

    

 

Section
2.             Exercise.

 

a)             Exercise
of Warrant.

 

i.
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after
the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of
the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books
of the Company) of a duly executed notice of exercise (“Notice of Exercise”) form attached hereto as
Exhibit A; and, within three (3) Trading Days of the date said Notice of Exercise is delivered to the Company, the Company
shall have received payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s
check drawn on a United States bank. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant
has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three
(3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder
and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. In the event
of any dispute or discrepancy, the records of the Company shall be controlling and determinative in the absence of manifest error.

 

ii.
If at any time after the Initial Exercise Date, in lieu of the payment methods set forth in Section 2(a)(i) above, the
Holder may elect to exchange all or some of this Warrant for shares of Common Stock equal to the value of the amount of the Warrant
being exchanged on the date of exchange.  If Holder elects to exchange this Warrant as provided in this Section 2(a)(ii),
Holder shall tender to the Company the Warrant for the amount being exchanged, along with written notice of Holder’s election
to exchange some or all of the Warrant, and the Company shall issue to Holder the number of shares of the Common Stock computed
using the following formula:

 

	X
    =	Y
    (A-B)
	 	A

 

	 	Where:      X
    =	the
number of shares of Common Stock to be issued to Holder.

	 	 	 
	 	  Y
    =  	the
    number of shares of Common Stock purchasable under the amount of the Warrant being exchanged (as adjusted to the date of such
    calculation).
	 	 	 
	 	  A
    =  	the
    Fair Market Value of one share of the Common Stock on the date that the notice of exercise is received by the Company.
	 	 	 
	 	B
=  	Exercise
    Price (as adjusted to the date of such calculation).

 

b)             Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $0.08 subject to adjustment hereunder
(the “Exercise Price”).

 

    	 	 	3

     

    

 

c)             Exercise
Limitations. Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise,
to the extent that after giving effect to such issuance after exercise, the Holder (together with the Holder’s affiliates,
and any other person or entity acting as a group together with the Holder or any of the Holder’s affiliates), would beneficially
own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of this Section, beneficial ownership shall
be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. Holder
is solely responsible for any schedules required to be filed in accordance therewith. The Company shall have no obligation to
verify or confirm the accuracy of such filings. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its affiliates
since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership
Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of Warrant Shares issuable upon exercise of this Warrant. The Holder, upon not less than 61 days’ prior
notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(c), provided
that the Beneficial Ownership Limitation may not exceed 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this
Section 2(c) shall continue to apply, unless the Holder upon not less than 61 days’ prior notice to the Company determines
to waive the Beneficial Ownerhship Limitation requirements described in this Section 2(c) in its entirety. Any such increase or
decrease will not be effective until the 61st day after such notice is delivered to the Company. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.

 

d)             Mechanics
of Exercise.

 

i.             Delivery
of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be transmitted by the Company’s transfer
agent (the “Transfer Agent”) to the Holder by crediting the account of the Holder’s prime broker
with the Depository Trust Company through its Deposit Withdrawal Agent Commission (“DWAC”) system if
the Company is then a participant in such system and either (A) there is an effective registration statement permitting the resale
of the Warrant Shares by the Holder or (B) the shares are eligible for resale without volume or manner-of-sale limitations pursuant
to Rule 144, and otherwise by physical delivery of certificates to the address specified by the Holder in the Notice of Exercise
within four (4) Trading Days from the delivery to the Company of the Notice of Exercise Form, surrender of this Warrant (if required)
and payment of the aggregate Exercise Price as set forth above (the “Warrant Share Delivery Date”).
This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by the Company. The Warrant Shares
shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have
become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised by payment to the Company
of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section 2(e)(vi) prior to the issuance
of such shares, have been paid.

 

ii.            Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant
Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for
by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

    	 	 	4

     

    

 

iii.           Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder a certificate or the certificates representing
the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind
such exercise.

 

iv.          No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.

 

v.           Charges,
Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or
transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall
be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name other
than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the assignment form (“Assignment
Form”) attached hereto as Exhibit B duly executed by the Holder and the Company may require, as a condition thereto,
the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.

 

vi.          Closing
of Books. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of
this Warrant, pursuant to the terms hereof.

 

e)             Redemption
of Warrants.

 

i.            General.
Prior to the Termination Date, commencing 12 months following the Issue Date, the Company shall have the option, subject to the
conditions set forth herein, to redeem all of the Warrant then outstanding upon not less than thirty (30) days prior written notice
to the Holder provided that, at the time of delivery of such notice theVWAP of the Company's Common Stock for a period
of 10 consecutive Trading Days is $0.20 per share or greater, as proportionately adjusted to reflect any stock splits, stock dividends,
combination of shares or like events.

 

ii.            Notice.
Notice of redemption will be effective upon mailing in accordance with this Section and such date may be referred to below as
the “Notice Date.” Notice of redemption shall be mailed by first class mail, postage prepaid, by the
Company not less than 30 days prior to the date fixed for redemption to the Holders of the Warrants to be redeemed at their last
addresses as they shall appear on the registration books. Any notice mailed in the manner herein provided shall be conclusively
presumed to have been duly given whether or not the Holder received such notice.

 

iii.           Redemption
Date and Redemption Price. The notice of redemption shall state the date set for redemption, which date shall be not less
than thirty (30) days from the Notice Date (the “Redemption Date”). The Company shall not mail the notice
of redemption unless all funds necessary to pay for redemption of the Warrant to be redeemed shall have first been set aside by
the Company for the benefit of the Holder so as to be and continue to be available therefor. The redemption price to be paid to
the Holder will be $0.0001 for each share of common stock of the Company to which the Holder would then be entitled upon exercise
of the Warrant being redeemed, as adjusted from time to time as provided herein (the “Redemption Price”).

 

    	 	 	5

     

    

 

iv.          Exercise. Following the Notice Date, the Holder may exercise their Warrants between the Notice Date and 5:00 p.m. Eastern
Time on the Redemption Date at a price equal to 25% of the Exercise Price and such exercise shall be timely if the form of election
to purchase duly executed and the Exercise Price for the shares of Common Stock to be purchased are actually received by the Company
at its principal offices prior to 5:00 p.m. Eastern Time on the Redemption Date.

 

v.           Mailing.
If any Holder does not wish to exercise any Warrant being redeemed, he should mail such Warrant to the Company at its principal
offices after receiving the notice of redemption. On and after 5:00 p.m. Eastern Time on the Redemption Date, notwithstanding
that any Warrant subject to redemption shall not have been surrendered for redemption, the obligation evidenced by all Warrants
not surrendered for redemption or effectively exercised shall be deemed no longer outstanding, and all rights with respect thereto
shall forthwith cease and terminate, except only the right of the holder of each Warrant subject to redemption to receive the
Redemption Price for each share of Common Stock to which he would be entitled if he exercised the Warrant upon receiving notice
of redemption of the Warrant subject to redemption held by him.

 

Section
3.              Certain Adjustments.

 

a)             Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b)             Pro
Rata Distributions. If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common
Stock (and not to the Holder) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants
to subscribe for or purchase any security other than the Common Stock, then in each such case the Exercise Price shall be adjusted
by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled
to receive such distribution by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned
above, and of which the numerator shall be such VWAP on such record date less than the per share Fair Market Value at such record
date of the portion of such assets or evidence of indebtedness or rights or warrants so distributed applicable to one outstanding
share of the Common Stock as determined by the Board of Directors in good faith. In either case the adjustments shall be described
in a statement provided to the Holder of the portion of assets or evidences of indebtedness so distributed or such subscription
rights applicable to one share of Common Stock. Such adjustment shall be made whenever any such distribution is made and shall
become effective immediately after the record date mentioned above.

 

    	 	 	6

     

    

 

c)            Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company effects any merger or consolidation of the
Company into another Person, (ii) the Company effects any sale of all or substantially all of its assets in one or a series of
related transactions, (iii) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant
to which holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property or (iv)
the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock
is effectively converted into or exchanged for other securities, cash or property (each “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would
have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, the number of shares
of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental
Transaction. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply
to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are
given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Company or surviving entity
in such Fundamental Transaction shall issue to the Holder a new warrant consistent with the foregoing provisions and evidencing
the Holder’s right to exercise such warrant into Alternate Consideration. The terms of any agreement pursuant to which a
Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions
of this Section 3(c) and insuring that this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent
transaction analogous to a Fundamental Transaction.

 

d)            Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

e)            Notice
to Holder.

 

i.              Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall
promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement
of the facts requiring such adjustment.

 

    	 	 	7

     

    

 

ii.             Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of
the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become
effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange
their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation,
merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing
thereof shall not affect the validity of the corporate action required to be specified in such notice. The Holder is entitled
to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice.

 

Section
4.              Transfer of Warrant.

 

a)             Transferability.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) herein and to the provisions
of the Subscription Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights)
are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder
or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or
assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
The Warrant, if properly assigned, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant
issued.

 

b)            New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial
Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

    	 	 	8

     

    

 

c)             Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.

 

d)             Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and
under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions pursuant
to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant,
as the case may be, comply with the provisions of the Subscription Agreement.

 

Section
5.              Miscellaneous.

 

a)             No
Rights as Shareholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights as a shareholder
of the Company prior to the exercise hereof.

 

b)             Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)             Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

d)             Authorized
Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock one hundred (100%) of the number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase
rights under this Warrant. In case such amount of Common Stock is insufficient at any time, the Company shall call and hold a
special meeting to increase the number of authorized shares of common stock. Management of the Company shall recommend to shareholders
to vote in favor of increasing the number of authorized shares of common stock.

 

The
Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise
of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that
such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of the National Securities Exchange upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which
may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights
represented by this Warrant, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and
charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).

 

    	 	 	9

     

    

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its amended and restated certificate of incorporation, as amended, or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such
terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in
this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value
of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii)
take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and
nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such
authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable
the Company to perform its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e)             Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Subscription Agreement.

 

f)             Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions
upon resale imposed by state and federal securities laws.

 

g)             Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all
rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision
of this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts as shall be
sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of
appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.

 

    	 	 	10

     

    

 

h)             Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Subscription Agreement.

 

i)              Limitation
of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for
the purchase price of any Common Stock or as a shareholder of the Company, whether such liability is asserted by the Company or
by creditors of the Company.

 

j)              Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.

 

k)             Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder. The provisions
of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be enforceable by
the Holder or holder of Warrant Shares.

 

l)             Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

m)            Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

n)             Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.

 

[Signature
Page Follows.]

 

    	 	 	11

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

	ORIGINCLEAR, inc. 

	 
	 	 	 
	By:
	                	 
		Name:	 
		Title:	 

 

 

12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]